High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097

Interest continues to build around the early application of patient selection markers to prospectively identify patients likely to show clinical benefit from cancer therapies. Hypothesis generation and clinical strategies often begin at the preclinical stage where responder and nonresponder tumor ce...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: He, Wei, Luistro, Leopoldo, Carvajal, Daisy, Smith, Melissa, Nevins, Tom, Yin, Xuefeng, Cai, James, Higgins, Brian, Kolinsky, Kenneth, Rizzo, Christine, Packman, Kathryn, Heimbrook, David, Boylan, John F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2011
Soggetti:
Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528291/
https://ncbi.nlm.nih.gov/pubmed/21315665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.01.001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi